AlphaFold predicted structure
INPP5K · Q9BT40

Mean pLDDT
88.4/ 100
Confident
448 residues
Confidence breakdown
- Very high(≥ 90)72%
- Confident(70–90)16%
- Low(50–70)7%
- Very low(< 50)5%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
inositol polyphosphate-5-phosphatase K
Annotations refreshed 9 hours ago.
Diagnostic Grade (Green)
Bilateral congenital or childhood onset cataracts
BIALLELIC, autosomal or pseudoautosomalCongenital muscular dystrophy
BIALLELIC, autosomal or pseudoautosomalDDG2P
BIALLELIC, autosomal or pseudoautosomalIntellectual disability
BIALLELIC, autosomal or pseudoautosomalFetal anomalies
BIALLELIC, autosomal or pseudoautosomalmuscular dystrophy, congenital, with cataracts and intellectual disability
atrial fibrillation
atrial flutter
congenital muscular dystrophy
congenital myopathy
hereditary disease
neurodegenerative disease
Sjogren syndrome
muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B1
distal myopathy
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Inositol polyphosphate 5-phosphatase K
Inositol 5-phosphatase which acts on inositol 1,4,5-trisphosphate, inositol 1,3,4,5-tetrakisphosphate, phosphatidylinositol 4,5-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate (PubMed:10753883, PubMed:16824732). Has 6-fold higher affinity for phosphatidylinositol 4,5-bisphosphate than for inositol 1,4,5-trisphosphate (PubMed:10753883). Negatively regulates assembly of the actin cytoskeleton. Controls insulin-dependent glucose uptake among inositol 3,4,5-trisphosphate phosphatases; therefore, is the specific regulator for insulin signaling in skeletal muscle (By similarity)
INPP5K · Q9BT40

Mean pLDDT
88.4/ 100
Confident
448 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0